Translating Predictive and Prognostic Breast Cancer Biomarkers to the Clinic
| Period from: | 2008-10-01 to: 2009-09-30 |
| Principal Investigators: | Drs. Mark Basik and Morag Park |
| Co-Investigators: | Sylvie Mader; Gerald Batist; Michael Hallett; William Muller |
| Department: | Surgery & Oncology |
| Partner: | Canadian Partnership Against Cancer Corporation |
| Program: | Biomarker Pilot Research Project |
| Abstract: |
Mapping of the human genome, coupled with the development of microarray technologies, has permitted the identification of molecular changes that underlie the initiation and progression of breast cancer.
While such approaches have led to the development of many novel targeted therapies, the efficacy of these agents is incomplete. A deeper understanding of molecular factors responsible for primary and acquired resistance to these new therapies is essential to select patients most likely to benefit from them and provide an expanded repertoire of alternative therapies.
We have identified several prognostic biomarkers and gene signatures that predict clinical outcome and metastatic progression in breast cancer. These markers may themselves be important therapeutic targets that may lead to the development of novel agents for treatment of the disease. We will validate previously identified novel biomarkers and gene signatures as predictive and prognostic indicators for resistance to existing and developing therapeutics, as decision-making tools for therapeutic intervention, and to drive the design of new clinical trials.
|
| Funding Information: | |
| 2008-2009 | $81,525 |
| 2009-2010 | $81,525 |
| TOTAL | $163,050 |
|
 |
